Enterovirus 71 (HEV71) epidemics in children and infants result mainly in mild symptoms; however, especially in the Asia-Pacific region, infection can be fatal. At present, no therapies are available. We have used structural analysis of the complete virus to guide the design of HEV71 inhibitors. Analysis of complexes with four 3-(4-pyridyl)-2-imidazolidinone derivatives with varying anti-HEV71 activities pinpointed key structure-activity correlates. We then identified additional potentially beneficial substitutions, developed methods to reliably triage compounds by quantum mechanics-enhanced ligand docking and synthesized two candidates. Structural analysis and in vitro assays confirmed the predicted binding modes and their ability to block viral infection. One ligand (with IC 50 of 25 pM) is an order of magnitude more potent than the best previously reported inhibitor and is also more soluble. Our approach may be useful in the design of effective drugs for enterovirus infections. npg
a r t i c l e s
The large Picornaviridae family includes pathogens with major impacts on human and animal health. However there are, as yet, no approved therapies for picornavirus infections. The enteroviruses compose the largest picornavirus genus. Of these, human enterovirus 71 (HEV71) presents perhaps the greatest threat to public health after the human rhinoviruses responsible for most cases of the common cold. HEV71 is responsible for periodic disease outbreaks throughout the world, and in recent years there have been regular major epidemics in South Asia. These are associated with outbreaks of mild childhood exanthema, herpangina and hand, foot and mouth disease. However, especially in the Asia-Pacific region, fatal neurological and cardiovascular disorders can ensue 1 . Picornaviruses are small positive-stranded RNA viruses with nonenveloped icosahedral capsids comprising 60 copies of proteins VP1-VP4. Proteins VP1-VP3 each adopt a β-barrel configuration and are arranged with icosahedral symmetry such that VP1 surrounds the five-fold axes, and VP2 and VP3 alternate about the two-and three-fold axes (with VP4 being internal) 2 . Canyon-like depressions encircling the five-fold axes in enteroviral capsids are frequently the sites of receptor attachment (Fig. 1a) . Uncoating, whereby the capsid opens to release the viral genome into the hostcell cytosol in order to replicate, is key to picornavirus infection. Like most enteroviruses, HEV71 contains within its capsid 60 copies of a hydrophobic 'pocket factor' , a natural lipid (sphingosine), buried in a pocket lying at the base of the canyon in the capsid protein VP1 (Fig. 1a) . Expulsion of this molecule after binding of the virus to its receptor triggers a cascade of structural rearrangements, which open the capsid to facilitate genome release 3, 4 . Because expulsion of the pocket factor is required for infection, a tight replacement binder could be a useful antiviral agent acting on the virus capsid. Pleconaril and BTA798 are two examples of several classes of lowmolecular-weight hydrophobic compounds identified 5, 6 to inhibit viral uncoating by such stabilization of the capsid 7, 8 . Although no antipicornavirus drug has yet been licensed, the two aforementioned compounds have completed phase II clinical trials. BTA798 (refs. 9,10) , developed by Biota Holdings, continues to show promise for asthmatic patients with rhinovirus infections 10 . From the skeletons of Pleconaril 11 and related molecules, a new class of imidazolidinones has been synthesized with anti-HEV71 activity (half-maximal inhibitory concentration (IC 50 ) in the range of 0.001-25 µM (refs. 12, 13) , and the crystal structure of the HEV71 particle 4, 14, 15 now provides an opportunity for the rational improvement of such inhibitors 15 . The use of crystal structures of proteinligand complexes in combination with in silico methods to guide antiviral inhibitor design is now well established as an effective strategy, with a notable early example being development of the first useful anti-influenza drug 16 . Nevertheless the use of whole viruses as targets has not been routinely integrated into pharmaceutical pipelines, and it is well known that existing in silico methods have usually struggled to rank compounds by binding affinity 17 .
We set out to design more-effective small-molecule antivirals targeting HEV71, on the basis of structural information. To this end, we analyzed the experimentally derived high-resolution structures of HEV71 bound to four 3-(4-pyridyl)-2-imidazolidinone derivatives ( Fig. 1b) 12 , using robust in silico docking methods to rank potential new inhibitors. We designed a number of compounds, triaged them in silico and synthesized two. We used efficient in situ crystallography 18 to determine inhibited capsid structures, demonstrating that the compounds bound as expected to the virus and further showing that they inhibited infection. One of these compounds is an order of magnitude more potent than the previous best inhibitor.
RESULTS

Structural basis of 3-(4-pyridyl)-2-imidazolidinone activity
We determined the structures of HEV71 in complex with the uncoating inhibitors GPP2, GPP3, GPP4 and GPP12 (3-(4-pyridyl)-2imidazolidinone derivatives; defined in Figs. 1 and 2 and Table 1 ). Because these, and most pocket-factor analogs, are rather insoluble, we dissolved them in DMSO before soaking them into preformed HEV71 crystals (Online Methods). We collected data at room temperature in crystallization plates at the Diamond Light Source 18 , producing structures at between 2.65-and 2.8-Å resolution (Online Methods and Table 1 ). As seen from the electron density maps, the compounds replace the natural pocket factor (modeled as sphingosine), with only small shifts (0.1 Å-0.4 Å) in the backbone of the residues lining the pocket, thus reflecting their shape similarity with sphingosine ( Supplementary Fig. 1 ). The surface area accessible to solvent, calculated by Areaimol 19 , is 8 Å 2 for GPP3, 11 Å 2 for GPP2, 12 Å 2 for GPP4, 9 Å 2 for GPP12 and 9 Å 2 for the natural pocket factor. These results demonstrate that all of these molecules are essentially fully buried, with GPP3 perhaps inserted slightly deeper into the pocket. All compounds bind with their pyridine ring close to the entrance of the pocket, with the carbonyl oxygen of the imidazole moiety hydrogen-bonding to the backbone nitrogen of residue Ile113, as seen with sphingosine, and the phenoxy ring sandwiched between two phenylalanines (Phe135 and Phe155) ( Fig. 2) . The introduction of a methyl group in the GPP3 linker region results in an order of magnitude tighter binding compared to that of GPP2 ( Figs. 1 and 3a) . 
In silico docking
We assembled a database of published inhibition data for 47 HEV71 inhibitors 12, 13, 20 ( Supplementary Table 1 ) and generated correlation plots between the published IC 50 values 12, 13, 20 and the energy of interaction computed from the inhibitors' docking poses in the VP1 pocket for quantum mechanics-polarized ligand docking (QMPLD) 21 implemented in the Schrödinger suite (http://www.schrodinger.com/). We tested several docking methods (details in Supplementary Note and Supplementary Fig. 2) , and of these the QMPLD 21 method provided a compelling correlation of 0.81 (Fig. 3b) .
The quantum-mechanical optimized procedure reliably predicted the experimentally observed poses (Supplementary Fig. 3 ). In particular, the predicted docking poses of GPP2 and GPP3 had r.m.s. deviations of less than 2 Å from the crystal structures ( Supplementary  Fig. 3 ). We determined the template structure used for the docking at 2.65-Å resolution, and to test the robustness of the method we repeated some of these experiments by independent structure determinations, both at a similar resolution 15 (2.7 Å) and also at much lower resolution 14 Figure 1 The inhibitor-binding site and selected inhibitor structures. (a) The organization of the HEV71 inhibitor-binding pocket, lying below the canyon floor, shown occupied by a natural pocket factor (PF). An icosahedral five-fold axis is marked. VP1 subunits are shown as a cyan surface. A segment around the five-fold axis is cut away to reveal two pockets. (b) A selection of 3-(4-pyridyl)-2-imidazolidinone derivative structures, ranked according to their EC 50 value. The EC 50 values are: GPP3, 10 nM; GPP2, 100 nM; GPP12, 1.3 µM; GPP4, 1.6 µM and GPV13, 40 µM. The following chemical moieties are labeled in GPP3: A, pyridine ring; B, imidazole moiety; C, phenoxy group. a r t i c l e s npg a r t i c l e s a structure of rather low resolution can accurately reproduce the correct binding mode (Supplementary Fig. 4 ).
Plate-based inhibitor characterization
Using inhibitors GPP3 and GPP2, we next validated particle thermostability as a measure of compound potency by using a platebased high-throughput thermofluor assay (particle stability thermal release assay (PaSTRy)) 22 developed to assess viral stability and the dynamics of uncoating 3, 4 . For a negative control, we used 1-[(2chlorophenoxy)methyl]-4-[(2,6-dichlorophenyl)methoxy]-benzene (GPV13), a compound similar to SCH47820, which shows strong activity against poliovirus type 2 and several echoviruses and Coxsackieviruses but only weak activity against HEV71 (ref. 9) . The temperature at which purified virus releases its RNA genome (T R ) is ~58 °C. However, after incubation with 200 µg/ml GPV13, GPP3 or GPP2 for 72 h at room temperature, the T R was raised to 60-61 °C (Fig. 3c) , indicative of stabilization of the particle. At the lower concentration of 20 µg/ml, GPP3 and GPP2 still showed increased particle stability after 24-h incubation, whereas GPV13 had little effect even after 72 h ( Fig. 3d) . These results are consistent (Fig. 3e ) and the higher-temperature transition corresponding to the protein melting. In contrast, only the highertemperature transition occurred after incubation with 200 µg/ml GPP3 or GPP2, and the T m peaks were sharper (Fig. 3f) .
Design of potentially improved HEV71 inhibitors
With these tools for assessing in silico docking and thermostability, we next used the structural data to steer the design of more-potent compounds. The binding pocket is more exposed in HEV71 than in most other picornaviruses 4, 14 . We postulated, on the basis of inspection of the pocket entrance at the bottom of the canyon, that introducing a functional group such as an amine or amide on the pyridine ring ( Fig. 3a) might simultaneously increase the solubility of the compound and enhance its affinity for the virion by allowing the formation of hydrogen bonds with polar residues (for instance, Q202 or D112) ( Fig. 3a) .
To test this hypothesis, we scanned the pocket surface in silico with a collection of probes (such as hydrophobic, amine cation, ester oxygen atom, methyl group and amine with lone pair), using GRID 23 to identify binding hotspots. An amine with a lone-pair probe identified a hotspot around residue D112 with an overall energy of interaction of −15 kcal mol −1 . This minimum became more pronounced (−17 kcal mol −1 ) when the probe was an amine cation. The region around Q202 is also a hotspot for binding the amine cation, with an interaction energy of −20 kcal mol −1 (Fig. 4a) . These results support the hypothesis that introducing an amino group on the pyridine ring would increase the overall binding energy, owing to the formation of a hydrogen bond with residues on the canyon floor. On this basis, we generated modifications of the GPP3 molecule in silico, exploring the effect of multiple substituents on the pyridine ring and replacing the pyridine with alternative moieties of different size. We generated several dozen possibilities (with PRODRG 24 ) and triaged them by visual inspection. We selected some six compounds including furan, isoxazole, pyrrole and amine-thiazole derivatives to take forward to the next stage of in silico ranking and chose four to be synthesized. Of these, two were produced readily, and MS confirmed that they were highly pure ( Supplementary Fig. 5 ).
We conducted in silico docking with the QMPLD method described above (Supplementary Note and Online Methods) for the two molecules synthesized, termed NLD and ALD (Fig. 4b,c) . NLD (molecular weight 448 Da) is a variant of GPP3 in which position 2 of the pyridine ring has been replaced with a primary amine (Fig. 4b) . The docking poses show this molecule engaged with its amino group and forming a hydrogen bond to the carbonyl group of Q202, thereby increasing the number of virus capsid-ligand interactions. To achieve this, docking flips the pyridine ring by 180° compared to its orientation in the HEV71-GPP3 complex. The second molecule, ALD (molecular weight 476 Da), has position 2 of the pyridine ring replaced with an amide (Fig. 4c) . The docking pose suggests that this substituent will form hydrogen bonds with the side chain of D112. The predicted IC 50 values were 2.6 pM and 0.8 pM for NLD and ALD, respectively (Fig. 3b) . The logP (logarithm of the n-octanol-water partition coefficient) for GPP3 is calculated to be 3.8, whereas for NLD and ALD this decreased to 3.6 and 3.0, respectively, thus suggesting that these compounds are rather more soluble than previous inhibitors. In addition, the theoretical absorption, distribution, metabolism and excretion (ADME-tox) properties (calculated with QikProp v3.6 in the Schrödinger suite and reported in Supplementary Table 2) appear favorable.
ALD and NLD readily replace the natural pocket factor
To establish whether and how ALD and NLD bound, we soaked them into HEV71 crystals. The compounds were indeed more soluble than the GPP series, and the soaking protocol used led to rapid degradation of the crystals. We therefore reduced the concentration of the compounds 550-fold to allow diffraction data to be collected and determined room-temperature structures at 2.75-Å resolution 18 . Both ligands maintain the key useful interactions described above (Fig. 5a,b) . The presence of the amide group on the pyridine moiety allows ALD to establish hydrogen bonds with the side chain of D112, exactly as predicted by in silico docking (Fig. 5b) . However for NLD, the crystal structure shows that the amine group on the pyridine moiety, rather than interacting with the peptide carbonyl moiety of Q202 as predicted by in silico docking, is rotated by almost 180° to interact instead with the side chain of D112, in a similar way a b a r t i c l e s to that observed for ALD ( Fig. 5b) . With the exception of this reorientation, the experimental results agree with the predicted docking poses (r.m.s. deviation <2 Å). To investigate the NLD docking, we used LigPrep (http://www.schrodinger.com/), which suggested that at pH 7 the pyridine nitrogen could be protonated. Redocking NLD with a protonated pyridine produced an essentially correct pose of similar energy (r.m.s. deviation of 0.5 Å in comparison to experimental result).
NLD and ALD are powerful HEV71 inhibitors in vitro
PaSTRy analysis confirmed that NLD and ALD are potent capsid stabilizers that enhance stabilization at modest concentrations relative to those of known tight binders such as GPP3 (Fig. 5c,d) .
Quantification for such tight binders is difficult because the concentrations of binding sites (60 times the virus concentration of 0.2 µM) and competing pocket factor (at least equal to the concentration of binding sites) are far above the binding constant for NLD and ALD. The concentration needed to produce thermal stabilization will therefore underestimate the IC 50 by orders of magnitude 25 . We therefore also compared the inhibitory activities of ALD and NLD to those of GPP3 and GPP4 by in vitro half-maximal tissue-culture infectious dose (TCID 50 ) assays in Vero cells. We used ten-fold serial dilutions of virus in the presence of different concentrations of the compounds and exposed control wells to the equivalent concentration of solvent (DMSO) to ensure no cytopathic effect on uninfected cells or on virus titer. NLD was the most effective inhibitor, with an IC 50 of ~0.025 nM, inhibiting the viral titer to below 5% at concentrations over 0.05 nM. GPP3 was the next most effective inhibitor, with an IC 50 of 0.319 nM. ALD has an IC 50 of 8.54 nM (although the TCID 50 results suggested a more complex biphasic effect). GPP4 did not display inhibitory effects at concentrations up to 1,000 nM (Fig. 5e) . Finally, we performed a further set of experiments to determine the TCID 50 for NLD and ALD against the full range of HEV71 subtypes and against CVA16, a related virus also responsible for hand, foot and mouth disease (Supplementary Table 3) . Encouragingly, the compounds were potent against all of these viruses. The measured affinity of NLD is in excellent agreement with that predicted in silico (Fig. 3b) ; however, the affinity of ALD is much weaker than predicted. Although it is possible that this reflects an error in the in silico predictions, the TCID 50 results suggested a biphasic effect, and it is also possible that there were either off-target effects or metabolism of the compound.
DISCUSSION
It has proved notoriously difficult to find useful therapies for picornaviral infections such as the common cold. At present, replacing the hydrophobic-pocket factors expelled from many picornaviruses as they uncoat the genome 4 by more robust binders 26, 27 is the most promising point for therapeutic intervention 5, 6 . To direct the discovery process, we determined crystal structures of HEV71 in complex with four ligands with a broad range of affinities. GPP4, the shortest of the four, only partially occupies the binding pocket and has the poorest EC 50 . This relationship reveals that there is an optimal drug size, which correlates with the efficiency of binding-molecules of the right length fill the pocket better and are better inhibitors. The inhibitors that satisfy this requirement also offer an aromatic moiety at the correct point to occupy a hydrophobic trap formed by Phe135 and Phe155. Indeed, in all crystal structures of picornavirus-inhibitor complexes a pair of hydrophobic residues are found at positions equivalent to those occupied by these aromatic residues in HEV71 (refs. 28, 29) . Thus, structures of rhinovirus 14 in complex with Pleconavir 30 and poliovirus 2 in complex with a Schering-Plough compound 31 show the antiviral agent located between the structurally equivalent residues Tyr128 and Tyr152, and Phe134 and Tyr159, respectively ( Supplementary  Fig. 6) . The presence of this hydrophobic trap constrains the extent of penetration of such inhibitors and hence the length of the molecule. Increasing the length of the inhibitor causes a misalignment of the phenoxy group with respect to Phe135 and Phe155, thus decreasing the binding energy and undermining the inhibitory effect. Conversely, in GPP4, which is shorter (bearing just an iodine atom at position 6 on a r t i c l e s the phenoxy group), the trap locks the molecule to result in a partially filled cavity (Fig. 2d) . Nearby, a methyl group in the linker region of GPP3 in large part fills a hydrophobic subpocket; consequently, GPP3 has the lowest EC 50 value (10 nM). The hydrophobic residues (Phe131, Ala133 and Met253) lining the subpocket leave some space that could possibly accommodate a slightly bigger substituent (Fig. 3a) . However, Chang et al. 20 have shown that phenyl, dimethyl, ethyl and propyl groups cannot fit, because they decrease the affinity. Similarly, in rhinovirus bulkier substituents are unfavorable 32 , so a methyl group is probably close to optimal. We have also demonstrated the utility of an extremely rapid platebased fluorescence assay for inhibitor binding, which replicates the rank order of previously reported in vitro assays. In addition, by measuring RNA accessibility alongside protein unfolding, we have found that potent inhibitors elevate the capsid conformational transition associated with genome release to the point at which the capsid proteins melt.
The QMPLD method 21 , with guidance from the observed crystal structures, provided reliable docking results and predictions of binding strength (correlation coefficient 0.81 against a database of 47 prior results). This method, used with care, predicted correct docking poses from a virus structure determined at only 3.7-Å resolution. The power of the method is presumably partly due to its use of quantum mechanics to take into account the ligand polarization of the protein environment during the docking process.
Using experimental structural data together with in silico mapping of the pocket entrance for additional polar interactions, we designed optimized inhibitors (Fig. 4b,c) bearing hydrophilic substituents, which offered the additional benefit of increasing the solubility 33 . The generated docking poses for two of these inhibitors, ALD and NLD, confirmed additional putative hydrogen bonds with the virus and suggested that they were likely to bind more tightly to HEV71 than do any previously reported compounds (Fig. 4b) .
Synthesized ALD and NLD were soluble and highly reactive with the virus crystals, and they replaced the pocket factor very effectively. Both contain flexible linker regions allowing them to adapt well to the shape of the binding pocket. ALD bound as predicted by QMPLD docking, whereas a portion of NLD assumed an alternative conformation. However, careful analysis of the protonation state of the molecule led to a revised docking that recapitulated the observed binding mode. In vitro analysis with the PaSTRy assay confirmed that both NLD and ALD are powerful capsid stabilizers, with NLD being more potent than the previous gold-standard compound, GPP3 (Fig. 5c,d) . IC 50 values from cell-based assays underlined the extraordinary potency of NLD, which was able to protect cells from HEV71 infection at a concentration of 25 pM (Fig. 5e ). Furthermore the compounds showed good activity against all HEV71 subtypes and against CVA16, results suggesting that such compounds might be broadly effective against the disease (Supplementary Table 3) . This is explained by the conservation of Asp112 of VP1, which forms a key interaction, across all these viruses.
In summary, using the complete virus capsid as a target, we have used a combined experimental and computational approach, starting from a prior compound with limited solubility and nanomolar-range effective concentrations, to obtain, in a single round of design, a nextgeneration picomolar-range inhibitor that is broadly effective and relatively soluble and has many drug-like properties. (The calculated ADME-tox properties of NLD (Supplementary Table 2) indicate that the molecules are predicted to have generally acceptable pharmacokinetic properties.) Previous experience shows that such inhibitors can generate drug-resistant mutations 34 . If this were to occur with these compounds, more work would be required-perhaps a further round of design to build in resilience to common mutations (as performed in Hopkins et al. 35 ). In conclusion, we propose that the approach we describe might facilitate the design of more-efficient inhibitors targeted at other enteroviruses, such as rhinoviruses, poliovirus and Coxsackieviruses.
METHODS
Methods and any associated references are available in the online version of the paper. Accession codes. Coordinates and structure factors for the six complexes have been deposited in the Protein Data Bank under accession codes 4CDQ (HEV71-GPP2), 4CDU (HEV71-GPP3), 4CDW (HEV71-GPP4), 4CDX (HEV71-GPP12), 4CEY (HEV71-NLD) and 4CEW (HEV71-ALD).
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
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